<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122758</url>
  </required_header>
  <id_info>
    <org_study_id>CHAIN</org_study_id>
    <secondary_id>IB1323/10PI</secondary_id>
    <nct_id>NCT01122758</nct_id>
  </id_info>
  <brief_title>Chronic Obstructive Pulmonary Disease (COPD) History Assessment In SpaiN (CHAIN)</brief_title>
  <acronym>CHAIN</acronym>
  <official_title>(COPD History Assessment In SpaiN): &quot;Estudio Sobre la Evolución Multidimensional de la Enfermedad Pulmonar Obstructiva Crónica (EPOC)&quot;.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cimera</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cimera</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research project CHAIN (COPD Assessment History in Spain): &quot;A Multidimensional Study on&#xD;
      the Evolution of Chronic Obstructive Pulmonary Disease (COPD)is a multicentre, observational&#xD;
      study conducted in several areas of Spain aimed to better define COPD natural history and its&#xD;
      phenotypes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational studies are needed to ascertain the natural history and progression of COPD,&#xD;
      and to better define its phenotypes. These two aspects are considered fundamental to a proper&#xD;
      evaluation of current (and future) COPD treatment options, and it could possibly justify the&#xD;
      limited impact of recent major drug trials.&#xD;
&#xD;
      Currently, there remain gaps in the natural history of patients with COPD. Most data are from&#xD;
      analysis of mild COPD patients or smokers, usually measuring only fall in FEV1, and both have&#xD;
      significant limitations in design and interpretation.&#xD;
&#xD;
      Studies in more severe patients with COPD have also been conducted mainly by studying lung&#xD;
      function, possibly influenced by the recommendations of current guidelines for disease&#xD;
      management. In recent years, we have more longitudinal data on changes in exercise capacity,&#xD;
      imaging, and biomarkers, among other variables of interest, but our knowledge is yet partial.&#xD;
&#xD;
      The research project CHAIN (COPD Assessment History in Spain): &quot;A Multidimensional Study on&#xD;
      the Evolution of Chronic Obstructive Pulmonary Disease (COPD) is a multicenter observational&#xD;
      study that will follow prospectively two cohorts: a) a COPD group active or former smokers&#xD;
      (COPD cohort) and b) a group of active smokers or former smokers without COPD (control&#xD;
      cohort). Both cohorts will be followed up for a period of at least 5 years, with visits every&#xD;
      12 months (and phone controls at least every 6 months). We will try to extend the monitoring&#xD;
      of the cohort up to 10 years. CHAIN is supported by the PII of COPD SEPAR&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To better determine COPD with a multidimensional assessment and the phenotypic progression of COPD</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Progression of the disease by degree of severity. - Effect of treatment on disease progression and variability of response according to phenotypes. - Geographical differences. - The impact of exacerbations. - The importance of comorbidities and</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>COPD cohort</arm_group_label>
    <description>Inclusion criteria:&#xD;
Patients ≥ 35 years.&#xD;
Diagnosis of COPD (GOLD PBD FEV1/FVC ratio &lt;0.70).&#xD;
Being in a stable phase of disease (8 weeks without exacerbation).&#xD;
Cummulative smoking ≥ 10 pack-years.&#xD;
Absence of asthma or other chronic respiratory disease that justify the ventilatory disorder (although a history of asthma is not an exclusion criteria);&#xD;
Absence of malignancy or very serious comorbidities that would prevent study completion.&#xD;
Exclusion criteria:&#xD;
Patients &lt;35 years.&#xD;
Recent exacerbation (&lt;8 weeks).&#xD;
Not giving written informed consent.&#xD;
Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,&#xD;
Diffuse bronchiectasis not associated with COPD.&#xD;
Presence of malignancy or very serious comorbidities that would prevent study completion.&#xD;
Difficulty to perform appropriate follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control cohort</arm_group_label>
    <description>Inclusion criteria:&#xD;
Patients ≥ 35 years.&#xD;
Absence of diagnosis of COPD (GOLD PBD FEV1/FVC ratio &gt;=0.70).&#xD;
Cummulative smoking ≥ 10 pack-years.&#xD;
Absence of asthma or other chronic respiratory disease that justify the ventilatory disorder (although a history of asthma is not an exclusion criteria);&#xD;
Absence of malignancy or very serious comorbidities that would prevent study completion.&#xD;
Exclusion criteria:&#xD;
Patients &lt;35 years.&#xD;
Not giving written informed consent.&#xD;
Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,&#xD;
Diffuse bronchiectasis not associated with COPD.&#xD;
Presence of malignancy or very serious comorbidities that would prevent study completion.&#xD;
Difficulty to perform appropriate follow-up.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      complete blood and serum samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be selected from the outpatient clinics, pulmonary function labs, and /&#xD;
        or pulmonology wards of each participating center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 35 years.&#xD;
&#xD;
          -  Diagnosis of COPD (GOLD PBD FEV1/FVC ratio &lt;0.70).&#xD;
&#xD;
          -  Being in a stable phase of disease (8 weeks without exacerbation).&#xD;
&#xD;
          -  Cummulative smoking ≥ 10 pack-years.&#xD;
&#xD;
          -  Absence of asthma or other chronic respiratory disease that justify the ventilatory&#xD;
             disorder (although a history of asthma is not an exclusion criteria);&#xD;
&#xD;
          -  Absence of malignancy or very serious comorbidities that would prevent study&#xD;
             completion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients &lt;35 years.&#xD;
&#xD;
          -  Recent exacerbation (&lt;8 weeks).&#xD;
&#xD;
          -  Not giving written informed consent.&#xD;
&#xD;
          -  Presence of asthma or other chronic respiratory disease justifying the ventilatory&#xD;
             disorder,&#xD;
&#xD;
          -  Diffuse bronchiectasis not associated with COPD.&#xD;
&#xD;
          -  Presence of malignancy or very serious comorbidities that would prevent study&#xD;
             completion.&#xD;
&#xD;
          -  Difficulty to perform appropriate follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ciro Casanova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Nuestra Señora de la Candelaria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ciro Casanova, MD</last_name>
    <email>casanovaciro@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joan B Soriano, MD</last_name>
    <phone>34971148437</phone>
    <email>jbsoriano@caubet-cimera.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ciro Casanova</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Canarias</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciro Casanova</last_name>
      <email>casanovaciro@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>40-50 additional centres throughout Spain</name>
      <address>
        <city>Bunyola</city>
        <zip>07110</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan B Soriano, 724</last_name>
      <phone>34971148437</phone>
      <email>jbsoriano@caubet-cimera.es</email>
    </contact>
    <contact_backup>
      <last_name>724 724 724, 724</last_name>
      <phone>34971148437</phone>
      <email>jbsoriano@caubet-cimera.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.separ.es</url>
    <description>SEPAR-Sociedad Española de Neumología y Cirugía Torácica</description>
  </link>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>May 11, 2010</study_first_submitted>
  <study_first_submitted_qc>May 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2010</study_first_posted>
  <last_update_submitted>November 27, 2012</last_update_submitted>
  <last_update_submitted_qc>November 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2012</last_update_posted>
  <responsible_party>
    <name_title>Dr Ciro Casanova</name_title>
    <organization>Hospital Universitario Nuestra Señora de la Candelaria</organization>
  </responsible_party>
  <keyword>Cohort</keyword>
  <keyword>COPD</keyword>
  <keyword>Natural history</keyword>
  <keyword>Phenotyping</keyword>
  <keyword>Smoking</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

